Preserved DNA from past clinical trials yields new information about a subtype of alcoholism.
O'Brien
Charles P
CP
D000077443:Acamprosate; D000427:Alcohol Deterrents / Q000627:therapeutic use; D000437:Alcoholism / Q000235:genetics* / Q000534:rehabilitation*; D000483:Alleles; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D006580:Genetic Carrier Screening; D006801:Humans; D009271:Naltrexone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D011613:Psychotherapy; D016032:Randomized Controlled Trials as Topic; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors* / Q000235:genetics*; D013654:Taurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
D000427:Alcohol Deterrents; D009292:Narcotic Antagonists; D017450:Receptors, Opioid, mu; D013654:Taurine; D009271:Naltrexone; D000077443:Acamprosate